Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Jun 2022
TGA approves Vyxeos
15 June 2022 - This marks the first TGA approval for Jazz Pharmaceuticals. ...
Posted by Michael Wonder on 15 Jun 2022
PHARMAC widens access to safe sex drug after 'overwhelming support'
15 June 2022 - PHARMAC is overhauling its criteria for prescriptions to an effective safe sex drug common to gay men. ...
Posted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
Posted by Michael Wonder on 15 Jun 2022
TGA approval of Kimmtrak
15 June 2022 - Tebentafusp is a bi-specific fusion protein. ...
Posted by Michael Wonder on 15 Jun 2022
Calls for 'blockbuster' osteoporosis drug to be made widely available
14 June 2022 - Experts want to see a new "blockbuster" drug made accessible for more patients suffering from osteoporosis. ...
Posted by Michael Wonder on 15 Jun 2022
PHARMAC announces first round of medicine funding decisions following $191 million pharmaceutical budget increase
15 June 2022 - PHARMAC today announces the first round of changes to medicines funding following its $191 million pharmaceutical ...
Posted by Michael Wonder on 14 Jun 2022
Empagliflozin (Jardiance) approved by MHRA as UK’s first effective treatment for symptomatic chronic heart failure regardless of ejection fraction
14 June 2022 - The MHRA has granted marketing authorisation for the use of empagliflozin (Jardiance) as a treatment for adults ...
Posted by Michael Wonder on 14 Jun 2022
FDA’s treatment of China developed drugs spurs demands for multiregional clinical trials
14 June 2022 - China’s ambition to become a leader in the biopharma industry has been clear in the last ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 14 Jun 2022
FDA should step in to help spur AI/ML standards
13 June 2022 - The US FDA should support the burgeoning integration of artificial intelligence and machine learning in medical ...
Posted by Michael Wonder on 14 Jun 2022
Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as a booster in individuals aged 18 and over
13 June 2022 - In Australia, Nuvaxovid is the first protein-based COVID-19 vaccine registered for use as a booster regardless ...
Posted by Michael Wonder on 14 Jun 2022
PHARMAC seeks views on access criteria for COVID-19 treatments
14 June 2022 - PHARMAC is seeking feedback on access criteria for two new COVID-19 treatments – tixagevimab with cilgavimab ...
Posted by Michael Wonder on 14 Jun 2022
Alnylam announces FDA approval of Amvuttra (vutrisiran), an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
13 June 2022 - First and only FDA approved treatment demonstrating reversal in neuropathy impairment with subcutaneous administration once every three ...
Posted by Michael Wonder on 13 Jun 2022
Amivas receives authorisation from the MHRA to market artesunate amivas (artesunate) in U.K. for initial treatment of severe malaria
13 June 2022 - Amivas Ireland announced today the MHRA has authorised the Company to commercialise its lead product, Artesunate ...
Posted by Michael Wonder on 13 Jun 2022
IP waiver for COVID vaccines misses the mark in vaccinating the world
14 June 2022 - Vaccinating the world remains a priority and proposals to weaken the intellectual property for COVID-19 vaccines ...